Diet Timing and Exercise Time to Prevent Muscle Loss in Postmenopausal Women
Tests early-day eating with afternoon or morning exercise in women with obesity and diabetes.
Plain-language title generated from the registry record
Registry title: Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes
Key facts
- Where
- Toulouse, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 70 years old?
Source: NCT07075133, who can take part
Where in France
- Rangueil hospitalToulouse, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07075133
- Record updated
- 1 June 2026
- Original description
The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpointRead full original descriptionShow less
Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes
The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint
Inclusion: Post-menopausal women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures); Age range 45-70 years; T2DM diagnosed for more than 1 year; Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors; Ability to sign written informed consent before any study-specific procedure; Subject considered as reliable and capable of adhering to protocol; Subjects with Body Mass Index (BMI)≥ 30 kg/m²; Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval).
Exclusion: Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea); Subjects with previous or present history of serious eating disorder; Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days; Women with menopause hormone replacement therapy; Subjects with HbA1c > 8%; Subjects with any of the following medical conditions:; Congestive cardiac failure; Stage 4 chronic kidney disease (i.e. eGFR < 30 ml/min/1.73 m2); Liver cirrhosis or chronic liver disease; Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study; Subjects not able to understand the informed consent form or fasting diary instructions.